The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Johnson & Johnson has reported Phase III data where CARVYKTI improved overall survival in patients with multiple myeloma.

This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer cachexia. Meanwhile, IMPACT Therapeutics senaparib has seen its phase ...

The trial enrolled chronic myeloid leukaemia patients irrespective of their T315I mutation status. Credit: Nemes Laszlo/Shutterstock. Enliven Therapeutics has reported the latest positive results from ...

The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.

The Phase III TEMPO-1 trial enrolled 529 adults, between the ages of 40 and 80, diagnosed with Parkinson’s for less than three years.

Longboard Pharmaceuticals has commenced the Phase III DEEp SEA Study of bexicaserin for treating seizures in Dravet syndrome ...

ProJenX and Unlearn partnered to implement genAI technology for a Phase I trial of prosetin for amyotrophic lateral sclerosis ...

FluMist is a live-attenuated influenza vaccine. Credit: PeopleImages.com – Yuri A via Shutterstock. The US Food and Drug ...

BALVERSA is available as a round, biconvex, film-coated tablet in 3mg, 4mg, or 5mg strengths. BALVERSA is an FGFR kinase inhibitor indicated for treating patients with locally advanced or metastatic ...

The landscape of clinical trials is rapidly evolving with the advent of digital transformation. One of the key innovations revolutionising the industry is electronic consent (econsent, e-Consent), a ...

Sarclisa® is the first approved anti-CD38 therapy along with standard-of-care treatment to treat newly diagnosed multiple myeloma. Sarclisa® (isatuximab-irfc) is indicated for the treatment of ...